Intracellular accumulation of hyperphosphorylated tau and extracellular aggregation of amyloid beta (Aβ) are pathological hallmarks in AD brains [3], and have been recognized as significant targets for pharmaceutical development of AD [1, 4, 5]. This evidence concerns the gene MAPT and Alzheimer disease.